Copiktra
Named-patient access overview. Copiktra is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Copiktra (duvelisib) is an oral dual inhibitor of phosphoinositide 3-kinase delta and gamma (PI3K-delta, PI3K-gamma) marketed by Secura Bio. The US Food and Drug Administration approved Copiktra in September 2018 for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies, and granted accelerated approval for relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies (the FL indication was subsequently withdrawn in the US in 2021). Copiktra is dosed at 25 mg orally twice daily in 28-day cycles, with Boxed Warnings for serious infections, diarrhoea or colitis, cutaneous reactions, and pneumonitis. Treatment is initiated and overseen by a haematologist with experience managing PI3K-inhibitor toxicity. Reserve Meds coordinates physician-led cross-border sourcing for international patients.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Copiktra
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Copiktra is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Copiktra in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Copiktra
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.